In this episode of the “CURE® Talks Cancer” podcast Mel Mann discusses his participation in the clinical trial for Gleevec and how it changed the trajectory of his life.
In 1998, Mel Mann received his first dose of Gleevec (imatinib) in a clinical trial to treat his leukemia, which was then determined to be terminal. In honor of 20 years since Gleevec’s FDA approval, he shared his story on the “CURE® Talks Cancer” podcast.
“That three years turned into 26 years, and it's going to be 27 years, it's getting close to that time,” Mann said. “My daughter, she was five, and she grew up to be a doctor herself. I celebrated 36 years of marriage, so 26 extra years with my wife. It's really a lifesaver. It's a miracle drug, but they do happen. And that's how they happen...through research, and just people getting on clinical trials.”
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.